Key Points
- CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock at an average price of $2.79, totaling $27,900. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- AC Immune shares were trading around $2.77, below both the 50-day and 200-day moving averages. The company has a market cap of about $281.9 million and a 52-week range of $1.60 to $4.00.
- The company recently reported Q1 earnings of -$0.19 per share, slightly beating estimates, and revenue of $1.40 million, well above expectations. Analysts currently have a Hold consensus with a median price target of $7.50.
AC Immune (NASDAQ:ACIU - Get Free Report) CEO Andrea Pfeifer sold 10,000 shares of the firm's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the transaction, the chief executive officer owned 3,820,288 shares in the company, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AC Immune Trading Down 0.7%
Shares of ACIU stock opened at $2.77 on Tuesday. The stock's fifty day moving average is $2.95 and its two-hundred day moving average is $3.08. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. The firm has a market capitalization of $281.90 million, a P/E ratio of -3.38 and a beta of 1.65. AC Immune has a fifty-two week low of $1.60 and a fifty-two week high of $4.00.
AC Immune (NASDAQ:ACIU - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $0.33 million. Research analysts expect that AC Immune will post -0.68 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ACIU has been the subject of a number of recent research reports. Wall Street Zen raised AC Immune from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. BTIG Research reaffirmed a "buy" rating and issued a $8.00 target price on shares of AC Immune in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $7.00 target price on shares of AC Immune in a research note on Friday, March 13th. Finally, Weiss Ratings downgraded AC Immune from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AC Immune has a consensus rating of "Hold" and a consensus price target of $7.50.
Read Our Latest Research Report on ACIU
Institutional Trading of AC Immune
A number of hedge funds and other institutional investors have recently modified their holdings of ACIU. EFG International AG acquired a new stake in shares of AC Immune during the 4th quarter worth about $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune during the 3rd quarter worth about $48,000. Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth about $51,000. Goldman Sachs Group Inc. increased its position in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock worth $58,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of AC Immune during the 3rd quarter worth about $63,000. 51.36% of the stock is owned by institutional investors and hedge funds.
AC Immune Company Profile
(
Get Free Report)
AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.
Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
